WARSAW, Ind., March 3, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, is pleased to announce the commercial launch of the Persona Medial Congruent Bearing and OsseoTi Tibial Sleeves for the Vanguard 360 Revision Knee System. These enhancements to Zimmer Biomet's Knee portfolio represent the expansion of two of the Company's flagship knee systems, and combine anatomically inspired designs with cutting-edge advances in implant engineering.
The Persona Medial Congruent Bearing
The Persona Medial Congruent Bearing, which complements Persona The Personalized Knee System, is designed to recreate a more natural feeling motion of the human knee by maximizing knee joint stability throughout the full range of motion. Engineered from studies of the morphology and kinematics of a natural, healthy knee, the Persona Medial Congruent Bearing represents the convergence of Zimmer Biomet's ultracongruent designs with personalized femoral components.
OsseoTi Tibial Sleeves: Inspired by BoneTM
OsseoTi Tibial Sleeves complement the Vanguard 360 Revision Knee System by addressing a wide range of cavitary defects commonly encountered in revision knee procedures. Based on a typical highly vascularized metaphyseal region1 of the tibia, these sleeves feature Zimmer Biomet's proprietary OsseoTi porous metal technology, and are designed to distribute the load through biologic fixation from the tibial plateau and stem to loads closer to the joint. Made of a cutting edge technology by printing the metal and porous structure together, it creates a truly unified three-dimensional porous homogenous construct that mimics cancellous bone architecture and modulus.2
OsseoTi Tibial Sleeves offer a wide variety of sizing and positioning options, and can be used separately, together or in conjunction with a block augment. These versatile sleeves are designed to be positioned independently or symmetrically within the tibia, resulting in an effective bone-conserving solution for addressing cavitary defects.
"As the market leader and a pioneer in knee replacement, Zimmer Biomet is absolutely focused on supporting surgeons with a steady cadence of innovative clinical portfolio enhancements that set new standards at every stage of care, including total primary and revision procedures," said Todd Davis, Vice President & General Manager of the global Knee business. "In keeping with our long heritage of musculoskeletal innovation, these additions to Persona The Personalized Knee System, and the Vanguard 360 Knee Revision System are designed to empower surgeons to deliver personalized outcomes for their patients, while offering compelling clinical and economic value to healthcare systems around the globe."
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities, and trauma products; spine, bone healing, craniomaxillofacial, and thoracic products; dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "aims," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negatives of such terms or other variations on such terms or comparable terminology. Forward-looking statements include, but are not limited to, statements concerning products and services offered by Zimmer Biomet, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this communication are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this communication.
1 Haidukewych, George J. et al. Metaphyseal Fixation in Revision Total Knee Arthroplasty: Indications and Techniques, J Am Acad Orthop Surg 2011;19:311-318.
2 Biomet Test Report MT7196.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zimmer-biomet-announces-the-release-of-new-implant-technologies-in-support-of-the-persona-knee-system-and-vanguard-360-revision-knee-system-300230679.html
SOURCE Zimmer Biomet Holdings, Inc.